Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples